# Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients

> **NCT03352674** · PHASE2 · COMPLETED · sponsor: **Indonesia University** · enrollment: 133 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Insulin Glargine Ezelin
- **DRUG:** Insulin Glargine Pen Injector [Lantus]

## Key facts

- **NCT ID:** NCT03352674
- **Lead sponsor:** Indonesia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2018-12-01
- **Final completion:** 2018-12-01
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2020-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03352674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03352674, "Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03352674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*